Hikma shrugs off Middle East unrest

12th May 2011 12:07

Hikma Pharmaceuticals said it was on track to hit growth forecasts, with its operations businesses in Egypt, Tunisia and Bahrain performing well despite recent unrest.The Jordan-based firm said it was very pleased with the speed at which operations in these countries were returning to normal, although sales activities in Libya and Yemen remain limited.It said it would continue to closely monitor the effect the current unrest was having on its markets."Hikma is performing well, benefitting from the diversity of its business model," the firm said in a statement."We therefore maintain our 2011 group guidance of around 7% revenue growth and gross margin of around 47%, excluding the Multi-Source Injectables business."The firm will announce interim results for the six months to 30 June 2011 on 25 August 2011.